MSB Trading - 2019, page-37

Firstly, it's Col .....

.... and yes no one has a crystal ball, however I would have to hope that if a company puts out a Corporate Review announcement on the 28th December, 2018 saying this:

Mesoblast has one product candidate which has successfully completed Phase 3 and with near-term commercial potential in the United States (U.S.), another product candidate having achieved clinical outcomes in line with the U.S. Food and Drug Administration (FDA) guidance for a registrable clinical indication for market authorization, and two additional Phase 3 assets with blockbuster potential.

that some 9 days later on 7th January, 2019 it is going to report detrimental effects / bad news from these two phase 3 trials ? Just my opinion but I believe it would leave MSB wide open to litigation ?